Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • OS was not significantly different for durvalumab or for durvalumab plus tremelimumab compared with SoC. • The study was not designed to assess OS between immunotherapies, but adding tremelimumab did not appear to enhance durvalumab activity. • Failure to meet the primary end point may have been impacted by factors resulting in an unexpectedly long OS for the SoC arm.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.